Today’s our being website operator. be and available on for call you, webcast is will Thank replay.
you on regarding forward-looking Before to we opportunities details uncertainties, These for including and include financial and lines, risks and statements remind like filings development refer statements statements, risks. more position. you that time and and start, this to call partnership we time SEC our these clinical would are our our to plans lines will we subject
a this call is of As I recorded am Officer being Operating broadcast. reminder, for Jennifer audio Buell, Agenus. Chief
our me member the Chairman stating and CEO of to Christine Klaskin, innovation Joining Dhan President Business Chief Lucidi, AgenTus, Garo off a earlier our Fr. Bruno been start. our two of has file the first this filing trials, Therapy in team; Finance. designed by end Cell and Mr. Hence year, are in begin a may today BLA are Vice I which will of Entity; clinical XXXX. come these data faster means that our BLA able Dr. key Executive may before strong to anticipated of be is a Armen, XXXX trials Enrollment our and from we Officer; to than Chand; than which projections. earlier support
either both could or trials support trial know, you underway; two filings. have As registration we BLA
in monotherapy first cervical The is trial second-line trials PD-X our of cancer. these
with competitive also in like second-line state trial and to type strategy provide second combination combination The and an advantage others. cancer. cervical that is a important would I cancer PD-X us in this in of our CTLA-X, can
the plan next-gen second-generation We the opportunity CTLA-X be our commercial first-gen inflection potential our clinical AGENXXXX second-generation offers. trials proceeding. commence also CTLA-X our could CTLA-X for And of own from the second well PD-X own anticipate for point by best-in-class combination of in several potential of as enrollment to ability our value next molecule. monetize the CTLA-X, this believe Clinical very our end trial year. our on PD-X CTLA-X CTLA-X readouts our us what to expand also has it combination Secondly, beyond We commercial could to is a in ex-U.S. the early for data generation our We defining important a second-generation for U.S. of as months. represent this with right our our molecule. our
trials, responses. development product high more development rapid means and and combination on focus lower costs product durable well and as we responses discovery product on product registrations focused Our This achieving trial shorter is are registrations. as
our combinations vaccines. Our our therapies checkpoint combinations our our bispecifics, opportunities for with also cell antibodies, includes and
major with access strategy. products approval. and/or costly responses currently that Generally, high high accelerated to these define there for types options. which helps FDA on strategies our is designed advantage, less for shorter, We combination Our deliver trials impact tumor these rapidly high no are effective durable our agents to translate as address products impact ability a to or attributes which cancers treatment
a development discoveries to quality efficient us allow These more products line are manage GMP cell capabilities. at without be to ability to costs key internal larger to discovery antibody would from capabilities possible higher portfolio a to well. much development advantages and pipeline at integrated and our build these as costs Our of than a programs manufacturing lower quickly of and with
transaction the novel XXXX, discovery of the other antibodies. clinic, most already is to in the Today exciting will royalties. deliver two enabled Gilead months. in in our we $X.X Our enter potentially the innovation expected with oncology in entered largest upfront clinic billion to and the in investment additional has our cash, payments $XX preclinical One and plus in million $XXX speed highlight collaboration the million has equity drug us coming
Our is targeting unique these key Dhan same and you antibodies advantages over attributes to anti-CDXXX molecule, other best-in-class more AGENXXXX shortly. have their antibodies, unique going novel A molecules and Dr. receptors. tell contributor our Chand, to about the AGENXXXX second-generation CTLA-X, these potential
Bruno, undisclosed and Additionally, well. towards we candidates are year a employees, IND. pipeline significant advancing lead AgenTus. on time, AgenTus, call has our year. two on the of XX allogeneic for made track and Today, subsidiary, this INDs us of with single provide five was proprietary will a TCR CEO progress at cancer cell our and building for a are cell patients proprietary company to file therapy second-generation, with and our of progress bispecific is autologous TCR a currently programs CAR-T has and as AgenTus – candidate. this AgenTus, an the Last format this candidates the an robust for update team, advancing
QS-XX a first launch $X.X The the one earlier billion least malaria in large at been announced ever Lastly, in has in revenues year, this $X revenues this QS-XX vaccine. our year. over powered innovations each dies year. global product of than burden containing people year launch, and with to of vaccine is GSK’s Shingrix of trial catalysts have vaccine, GSK immense, XXX,XXX malaria Also, its the blockbuster more Mosquirix, reach the our it’s partners. for Sales important achieved first with our expected billion of for
this potential We are to excited of eradication deadly to disease. the contribute
process Finally, with to Foundation to ensure future the now Gates grant continuous of Garo. turn of supply manufacturing provided the this alternative $X the development I us over enable a of about of adjuvant. & will call Melinda QS-XX an important million Bill to